Abstract
Background: Plasma enriched in growth factors is widely used in medical practice. However, the clinical efficacy of its application in the treatment of age-related retinal integrity violations is investigated insufficiently. Aims: The aim of the study was to evaluate the clinical efficacy of autologous plasma enriched with platelet lysate for treating age-related macular degeneration. Materials and methods: A three-port subtotal transconjunctival vitrectomy was performed and administration of the autologous plasma enriched with platelet lysate was indicated. Autologous plasma enriched with platelet lysate was received from the peripheral blood. We assessed visual acuity, intraocular pressure; conducted optical coherent tomography examination of the eye on the side of the pathological process. Results: The study demonstrated that the combination of a standard 3-port transconjunctival subtotal vitrectomy followed by tamponade of the gap using the autologous plasma enriched with platelet lysate with the injections of the autologous plasma enriched with platelet lysate in the area of pterygopalatine fossa on the side of the operated eyes statistically significantly promoted recovery of the visual acuity in the early postoperative period (15 days) and late period (90 days) if compared with patients who received only surgical treatment (p≤0.05). Use of the autologous plasma enriched with platelet lysate in the treatment increased the closing rate of the tearing of the retina in the macular region up to 62,5%, while only surgical treatment leads to the closure of the defect of the retina in 37.5% of cases. The study showed that autologous plasma enriched with platelet lysate contains cytokines, growth factors, and nitric oxide which are involved in the regeneration/reparation of the retina. Conclusions: Additional administration of the autologous plasma enriched with platelet lysate in the scheme of treatment patients with age-related macular degeneration is accelerating the closure of retinal tears of the eye and improves visual acuity.
Highlights
Plasma enriched in growth factors is widely used in medical practice
Autologous Plasma Enriched with Platelet Lysate for the Treatment of Idiopathic Age-Related Macular Degeneration: A Prospective Study
The study demonstrated that the combination of a standard 3-port transconjunctival subtotal vitrectomy followed by tamponade of the gap using the autologous plasma enriched with platelet lysate with the injections of the autologous plasma enriched with platelet lysate in the area of pterygopalatine fossa on the side of the operated eyes statistically significantly promoted recovery of the visual acuity in the early postoperative period (15 days) and late period (90 days) if compared with patients who received only surgical treatment (p≤0.05)
Summary
Мешалкина», Новосибирск, Российская Федерация 3Межотраслевой научно-технический комплекс «Микрохирургия глаза» имени академика С.Н. Цель исследования ― оценка клинической эффективности лечения возрастной макулярной дегенерации аутологичной плазмой, обогащенной лизатом тромбоцитов. Обогащенной лизатом тромбоцитов, в схему лечения увеличивает частоту закрытия разрывов сетчатки глаза в макулярной области до 62,5%, тогда как только оперативное лечение приводит к закрытию дефекта сетчатки глаза в 37,5% случаев. Дополнительное введение аутологичной плазмы, обогащенной лизатом тромбоцитов, в схему лечения разрывов сетчатки глаза не только ускоряет закрытие дефектов, но и повышает остроту зрения. (Для цитирования: Лыков А.П., Суровцева М.А., Повещенко О.В., Станишевская О.М., Черных Д.В., Арбеньева Н.С., Братко В.И. Цель исследования ― оценка эффективности использо- ал Федерального государственного бюджетного научнования аутологичной плазмы, обогащенной лизатом тром- го учреждения «Федеральный исследовательский центр боцитов, в лечении возрастной макулярной дегенерации.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
